|
|
Treatment of nodular goiter based on “dimple corresponding” |
LI Xin′ai1 QI Shuo2 CHEN Xiaoheng2 LI Zhe2 LI Huilong2 DING zhiguo2 YANG Yapeng2 |
1.The First Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100101, China;
2.Department of Goiter, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China |
|
|
Abstract Nodular goiter in traditional Chinese medicine is called “gall”. It is traditionally believed that the pathogenesis of this disease is based on qi stagnation, syndrome of intermingled phlegm and blood stasis is main pathogenesis. For the disease syndrome differentiation, experts and scholars in different areas have different opinions. However, this disease has its own law of occurrence, development and evolution. On the basis of deficiency of vital qi and dysfunction of Zang Fu organs, qi stagnation, phlegm coagulation and blood stasis occur. Thyroid diseases often involve multiple systems in the whole body, that is, the disease is located in the thyroid gland, involving multiple systems, and the thyroid gland is integrated with the whole body, that is, “dimple corresponding”. This paper will start from the pathogenesis, clinical manifestations, treatment prescriptions, expounds the academic thought of “dimple corresponding” theory in the treatment of nodular goiter.
|
|
|
|
|
[1] 田代华.黄帝内经素问[M].北京:人民卫生出版社,2005:1178.
[2] (隋)巢元方.诸病源候论[M].北京:中国医药科技出版社,2011:1135.
[3] 王象礼.陈无择医学全书[M].北京:中国中医药出版社,2005:190.
[4] 严用和.济生方[M].北京:中国医药科技,2015:1334-1335.
[5] (明)李梃.医学入门[M].北京:人民卫生出版社,2006:1776-1777.
[6] 陈继婷,傅汝林.陈慈煦副教授治疗甲状腺结节的经验介绍[J].贵阳中医学院学报,1981(2):8-11.
[7] (清)程国彭.医学心悟[M].北京:人民卫生出版社,2006:188-189.
[8] 梁未末.陈熠运用解郁法治疗桥本氏甲状腺炎经验介绍[J].新中医,2019,51(9):331-333.
[9] 林兰.现代临床中西医临床内分泌学[M].北京:中国中医药出版社,2001:76-78.
[10] 郑继生,金国梁.金国梁运用半夏厚朴汤加味治疗甲状腺结节的经验[J].浙江中医杂志,2010,45(4):252-253.
[11] 孙世宁.程益春教授治疗良性多发性甲状腺结节的经验[J].广西中医药,2011,34(5):44-45.
[12] 曹琳.余江毅教授从肝论治甲状腺结节经验精粹[J].辽宁中医药大学学报,2010,12(10):124-125.
[13] 赵华.李中南治疗甲状腺结节经验[J].河南中医,2012, 32(4):504.
[14] 何英,阙华发.阙华发运用温阳法治疗甲状腺结节经验[J].上海中医药杂志,2011,45(5):5-6.
[15] 张仲景.金匮要略[M].北京:中国医药科技出版社,2018:45-46.
[16] 田代华.黄帝内经素问[M].北京:人民卫生出版社,2005:177.
[17] (清)陈士铎.本草新编[M].北京:中国医药科技出版社,2011:1999.
[18] 施婧妮.鳖甲炮制前后抗肝纤维化药效物质及其质量分析比较研究[D].武汉:湖北中医药大学,2011.
[19] (明)李时珍.本草纲目[M].北京:人民卫生出版社,1957:245-247.
[20] 柳长华.神农本草经[M].北京:北京科学技术出版社,2015:188-189.
[21] 卢旻昱,刘铜华,侯毅,等.夏枯草的药理作用及研究进展述要[J].世界最新医学信息文摘,2019,19(31):31-33.
[22] 姚洋,李定祥,张杰.夏枯草药理作用与临床应用研究进展[J].中国中医药现代远程教育,2018,16(5):157-160.
[23] 赵秀梅.中药夏枯草的药理作用研究现状[J].内蒙古中医药,2016,35(12):120-122.
[24] 孙杰.黑三棱破血消癥作用的药理机制及活性成分研究[D].西安:西北大学,2011.
[25] 谭静,林红强,王亚茹,等.三棱的化学成分、药理作用及临床应用研究进展[J].特产研究,2018,40(4):109-113.
[26] 冯娅茹,张文婷,李二文,等.三棱化学成分及药理作用研究进展[J].中草药,2017,48(22):4804-4818.
[27] 张山雷.本草正义[M].太原:山西科学技术出版社,2013:198-199.
[28] 邴其忠,张本刚.“山慈菇”的本草考证[J].植物分类学报,2008(5):785-792.
[29] 赵许杰,闫雪生,孙丹丹.黄药子的药理作用和临床研究进展[J].药物评价研究,2012,35(2):147-149.
[30] 于培良,赵立春,廖夏云,等.荔枝核化学成分和药理活性研究进展[J].中国民族民间医药,2018,27(15):41-46.
[31] 张菊艳,张萃.荔枝核化学成分及其药理作用的研究进展[J].广东药学院学报,2014,30(6):792-797.
[32] 陈剑梅,郭洁文,徐峰.荔枝核活性成分提取及药理作用的研究进展[J].今日药学,2011,21(11):710-712, 720. |
|
|
|